Colombia vs Mauritius: Statin use vs. average non-HDL cholesterol levels
Colombia
3.7
in 2018
Mauritius
3.7
in 2018
Colombia rank
12th
Mauritius rank
12th
Statin use vs. average non-HDL cholesterol levels over time
- Colombia
- Mauritius
How they compare
Colombia currently reports 3.7 against 3.7 in Mauritius, a difference of 0.
The two have swapped places 2 times across 39 shared years of data; in 1980 it was Mauritius ahead.
Colombia ranks 12th and Mauritius ranks 12th of 191 countries.
Across the 4 decades both report, Colombia averaged higher in 3 and Mauritius in 1.
Head to head by decade
| Decade | Colombia | Mauritius | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.82 | 3.89 | 0.07 | Mauritius |
| 1990s | 3.9 | 3.79 | 0.11 | Colombia |
| 2000s | 3.85 | 3.7 | 0.15 | Colombia |
| 2010s | 3.74 | 3.7 | 0.0444 | Colombia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Colombia or Mauritius?
- Colombia, at 3.7 against 3.7 in Mauritius as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Colombia and Mauritius?
- 0, with Colombia ahead.
- How many years of comparable data are there for Colombia and Mauritius?
- 39 years are reported by both, from 1980 to 2018.
- How do Colombia and Mauritius rank globally for statin use vs. average non-hdl cholesterol levels?
- Colombia ranks 12th and Mauritius ranks 12th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.